|
Published by: Millennium Research
Published: May. 1, 2005
Table of Contents
- METHODOLOGY
- 1.0 ALLOSOURCE
- 1.1 Company Overview
- 1.2 Products Offered
- 1.3 Recent Events/Strategy
- 1.4 Financial Overview
- 1.5 S.W.O.T. Analysis
- 1.5.1 Strengths
- 1.5.2 Weaknesses
- 1.5.3 Opportunities
- 1.5.4 Threats
- 2.0 BIOMET
- 2.1 Company Overview
- 2.2 Products Offered
- 2.2.1 Bone Graft Substitutes
- 2.2.2 Hyaluronic Acid Viscosupplementation
- 2.2.3 Platelet Concentration Systems
- 2.2.4 Growth Factors
- 2.2.5 Machined Bone Products
- 2.3 Recent Events/Strategy
- 2.4 Financial Overview
- 2.5 S.W.O.T. Analysis
- 2.5.1 Strengths
- 2.5.2 Weaknesses
- 2.5.3 Opportunities
- 2.5.4 Threats
- 3.0 BIOMIMETIC PHARMACEUTICALS
- 3.1 Company Overview
- 3.2 Products Offered
- 3.3 Recent Events/Strategy
- 3.4 S.W.O.T. Analysis
- 3.4.1 Strengths
- 3.4.2 Weaknesses
- 3.4.3 Opportunities
- 3.4.4 Threats
- 4.0 CERAPEDICS
- 4.1 Company Overview
- 4.2 Products Offered
- 4.3 Recent Events/Strategy
- 4.4 S.W.O.T. Analysis
- 4.4.1 Strengths
- 4.4.2 Weaknesses
- 4.4.3 Opportunities
- 4.4.4 Threats
- 5.0 DEPUY (A J&J CO.)
- 5.1 Company Overview
- 5.2 Products Offered
- 5.2.1 Bone Graft Substitutes
- 5.2.2 Growth Factors
- 5.2.3 Platelet Concentration Systems
- 5.2.4 Other
- 5.3 Recent Events/Strategy
- 5.4 Financial Overview
- 5.5 S.W.O.T. Analysis
- 5.5.1 Strengths
- 5.5.2 Weaknesses
- 5.5.3 Opportunities
- 5.5.4 Threats
- 6.0 FIDIA FARMACEUTICI
- 6.1 Company Overview
- 6.2 Products Offered
- 6.2.1 Autologous Chondrocyte Implantation
- 6.2.2 Hyaluronic Acid Viscosupplementation
- 6.3 Financial Overview
- 6.4 S.W.O.T. Analysis
- 6.4.1 Strengths
- 6.4.2 Weaknesses
- 6.4.3 Opportunities
- 6.4.4 Threats
- 7.0 GENZYME BIOSURGERY (VERIGEN AG)
- 7.1 Company Overview
- 7.2 Products Offered
- 7.2.1 Products on the Market
- 7.2.2 Products in Development
- 7.3 Recent Events/Strategy
- 7.4 Financial Overview
- 7.5 S.W.O.T. Analysis
- 7.5.1 Strengths
- 7.5.2 Weaknesses
- 7.5.3 Opportunities
- 7.5.4 Threats
- 8.0 ISOTIS ORTHOBIOLOGICS
- 8.1 Company Overview
- 8.2 Products Offered
- 8.2.1 Bone Graft Substitutes
- 8.3 Recent Events/Strategy
- 8.4 Financial Overview
- 8.5 S.W.O.T. Analysis
- 8.5.1 Strengths
- 8.5.2 Weaknesses
- 8.5.3 Opportunities
- 8.5.4 Threats
- 9.0 MEDTRONIC SOFAMOR DANEK
- 9.1 Company Overview
- 9.2 Products Offered
- 9.2.1 Spinal Allografts
- 9.2.2 Bone Graft Substitutes
- 9.2.3 Growth Factors
- 9.3 Recent Events/Strategy
- 9.4 Financial Overview
- 9.5 S.W.O.T. Analysis
- 9.5.1 Strengths
- 9.5.2 Weaknesses
- 9.5.3 Opportunities
- 9.5.4 Threats
- 10.0 MUSCULOSKELETAL TRANSPLANT FOUNDATION
- 10.1 Company Overview
- 10.2 Products Offered
- 10.2.1 Bone Graft Substitutes
- 10.2.2 Spinal Allografts
- 10.2.3 Allofix Cortical Bone Pins and Screws
- 10.3 Recent Events/Strategy
- 10.4 Financial Overview
- 10.5 S.W.O.T. Analysis
- 10.5.1 Strengths
- 10.5.2 Weaknesses
- 10.5.3 Opportunities
- 10.5.4 Threats
- 11.0 ORTHOLOGIC
- 11.1 Company Profile
- 11.2 Products Offered
- 11.2.1 Chrysalin
- 11.3 Recent Events/Strategy
- 11.4 S.W.O.T. Analysis
- 11.4.1 Strengths
- 11.4.2 Weaknesses
- 11.4.3 Opportunities
- 11.4.4 Threats
- 12.0 ORTHOVITA
- 12.1 Company Profile
- 12.2 Products Offered
- 12.2.1 Bone Graft Substitutes
- 12.3 Recent Events/Strategy
- 12.4 Financial Overview
- 12.5 S.W.O.T. Analysis
- 12.5.1 Strengths
- 12.5.2 Weaknesses
- 12.5.3 Opportunities
- 12.5.4 Threats
- 13.0 OSTEOTECH, INC.
- 13.1 Company Overview
- 13.2 Products Offered
- 13.2.1 Spinal Allografts
- 13.2.2 Bone Graft Substitutes
- 13.3 Recent Events/Strategy
- 13.4 Financial Overview
- 13.5 S.W.O.T. Analysis
- 13.5.1 Strengths
- 13.5.2 Weaknesses
- 13.5.3 Opportunities
- 13.5.4 Threats
- 14.0 Q-MED
- 14.1 Company Overview
- 14.2 Products Offered
- 14.2.1 Hyaluronic Acid Viscosupplementation
- 14.3 Recent Events/Strategy
- 14.4 Financial Overview
- 14.5 S.W.O.T. Analysis
- 14.5.1 Strengths
- 14.5.2 Weaknesses
- 14.5.3 Opportunities
- 14.5.4 Threats
- 15.0 REGENERATION TECHNOLOGIES
- 15.1 Company Overview
- 15.2 Products Offered
- 15.2.1 Bone Graft Substitutes
- 15.2.2 Maxillofacial Fixation and BGS
- 15.2.3 Spinal Allografts
- 15.2.4 Sports Medicine Allografts
- 15.3 Recent Events/Strategy
- 15.4 Financial Overview
- 15.5 S.W.O.T. Analysis
- 15.5.1 Strengths
- 15.5.2 Weaknesses
- 15.5.3 Opportunities
- 15.5.4 Threats
- 16.0 SMITH & NEPHEW
- 16.1 Company Overview
- 16.2 Products Offered
- 16.2.1 Hyaluronic Acid Viscosupplementation
- 16.2.2 Cartilage Repair Products
- 16.2.3 Bone Graft Substitutes
- 16.3 Recent Events/Strategy
- 16.4 Financial Overview
- 16.5 S.W.O.T. Analysis
- 16.5.1 Strengths
- 16.5.2 Weaknesses
- 16.5.3 Opportunities
- 16.5.4 Threats
- 17.0 STRYKER CORPORATION
- 17.1 Company Overview
- 17.2 Products Offered
- 17.2.1 Growth Factors
- 17.2.2 Bone Graft Substitutes
- 17.3 Recent Events/Strategy
- 17.4 Financial Overview
- 17.5 S.W.O.T. Analysis
- 17.5.1 Strengths
- 17.5.2 Weaknesses
- 17.5.3 Opportunities
- 17.5.4 Threats
- 18.0 SYNTHES
- 18.1 Company Overview
- 18.2 Products Offered
- 18.2.1 Spinal Allografts
- 18.2.2 Bone Graft Substitutes
- 18.3 Recent Events/Strategy
- 18.4 Financial Overview
- 18.5 S.W.O.T. Analysis
- 18.5.1 Strengths
- 18.5.2 Weaknesses
- 18.5.3 Opportunities
- 18.5.4 Threats
- 19.0 TUTOGEN
- 19.1 Company Profile
- 19.2 Products Offered
- 19.2.1 Spinal Allografts
- 19.3 Recent Events/Strategy
- 19.4 Financial Overview
- 19.5 S.W.O.T. Analysis
- 19.5.1 Strengths
- 19.5.2 Weaknesses
- 19.5.3 Opportunities
- 19.5.4 Threats
- 20.0 WRIGHT MEDICAL TECHNOLOGIES
- 20.1 Company Overview
- 20.2 Products Offered
- 20.2.1 DBM Products
- 20.2.2 Synthetic Bone Graft Substitutes
- 20.2.3 Products in Development
- 20.3 Recent Events/Strategy
- 20.4 Financial Overview
- 20.5 S.W.O.T. Analysis
- 20.5.1 Strengths
- 20.5.2 Weaknesses
- 20.5.3 Opportunities
- 20.5.4 Threats
- 21.0 ZIMMER
- 21.1 Company Overview
- 21.2 Products Offered
- 21.2.1 Bone Graft Substitutes
- 21.3 Recent Events/Strategy
- 21.4 Financial Overview
- 21.5 S.W.O.T. Analysis
- 21.5.1 Strengths
- 21.5.2 Weaknesses
- 21.5.3 Opportunities
- 21.5.4 Threats
- 21.6 S.W.O.T. Analysis
- 21.6.1 Strengths
- 21.6.2 Weaknesses
- 21.6.3 Opportunities
- 21.6.4 Threats
- APPENDIX A: LIST OF ABBREVIATIONS
- List of Exhibits
- Chapter 1: AlloSource
- Exhibit 1-1: Select AlloSource Allograft Products, by Segment, 2004
- Exhibit 1-2: AlloSource Cartilage Repair Sales, US, 2004 (Tabular Format)
- Chapter 2: Biomet
- Exhibit 2-1: Biomet’s BGS Sales, by Country, 2004 (Tabular Format)
- Exhibit 2-2: Biomet’s PCS Sales, by Region, 2004 (Tabular Format)
- Exhibit 2-3: Biomet’s BGS Sales, by Country, 2004 (Graphical Format)
- Exhibit 2-4: Biomet’s PCS Sales, by Region, 2004 (Graphical Format)
- Chapter 3: BioMimetic Pharmaceuticals
- Exhibit 3-1: BioMimetic Pharmaceuticals Products Offered
- Chapter 5: DePuy (A J&J Company)
- Exhibit 5-1: DePuy’s BGS Sales, by Country, 2004 (Tabular Format)
- Exhibit 5-2: DePuy’s BGS Sales, by Country, 2004 (Graphical Format)
- Exhibit 5-3: DePuy’s Synthetic BGS Sales, US, 2004
- Exhibit 5-4: DePuy’s DBM Sales, US, 2004
- Exhibit 5-5: DePuy’s Sales, by Region, 2004 (Tabular Format)
- Exhibit 5-6: DePuy’s PCS Sales, by Country, 2004 (Graphical Format)
- Exhibit 5-7: DePuy Spine’s Machined Bone Sales, by Country, 2004
- Chapter 6: Fidia Farmaceutici
- Exhibit 6-1: Fidia’s ACI Sales, by Country, 2004 (Tabular Format)
- Exhibit 6-2: Fidia’s ACI Sales, by Country, 2004 (Graphical Format)
- Exhibit 6-3: Fidia’s HA Sales, by Country, 2004 (Tabular Format)
- Exhibit 6-4: Fidia’s HA Sales, by Country, 2004 (Graphical Format)
- Chapter 7: Genzyme Biosurgery (Verigen AG)
- Exhibit 7-1: Genzyme Biosurgery’s ACI Sales, US, 2004
- Exhibit 7-2: Verigen’s ACI Sales, by Country, 2004 (Tabular Format)
- Exhibit 7-3: Verigen’s ACI Sales, by Country, 2004 (Graphical Format)
- Exhibit 7-4: Genzyme Biosurgery’s HA Injection Sales, by Country, 2004 (Tabular Format)
- Exhibit 7-5: Genzyme Biosurgery’s HA Injection Sales, by Country, 2004 (Graphical Format)
- Chapter 8: IsoTis Orthobiologics
- Exhibit 8-1: IsoTis Orthobiologics’ DBM Sales, US, 2004
- Chapter 9: Medtronic Sofamor Danek
- Exhibit 9-1: Medtronic Sofamor Danek’s BGS Sales, by Type, US, 2004 (Tabular Format)
- Exhibit 9-2: Medtronic Sofamor Danek’s BGS Sales, by Type, 2004 (Graphical Format).77
- Exhibit 9-3: Medtronic Sofamor Danek’s Machined Bone Sales, US, 2004
- Exhibit 9-4: Medtronic Sofamor Danek’s PCS Sales, US, 2004
- Chapter 10: Musculoskeletal Transplant Foundation
- Exhibit 10-1: MTF’s DBM Sales, US, 2004
- Exhibit 10-2: MTF’s Machined Bone Sales, US, 2004
- Chapter 11: Orthovita
- Exhibit 12-1: Orthovita’s Synthetic BGS Sales, US, 2004
- Chapter 13: Osteotech
- Exhibit 13-1: Osteotech’s DBM Sales, US, 2004
- Chapter 14: Q-Med
- Exhibit 14-1: Q-Med’s HA Sales, by Country, 2004 (Tabular Format)
- Exhibit 14-2: Q-Med’s HA Sales, by Country, 2004 (Graphical Format)
- Chapter 15: Regeneration Technologies
- Exhibit 15-1: RTI’s BGS Sales, by Country, 2004 (Tabular Format)
- Exhibit 15-2: RTI’s BGS Sales, by Country, US$ Millions, 2004 (Graphical Format)
- Chapter 16: Smith & Nephew
- Exhibit 16-1: Smith & Nephew’s HA Injection Sales, by Country, 2004 (Tabular Format)
- Exhibit 16-2: Smith & Nephew’s HA Injection Sales, by Country, 2004 (Graphical Format)
- Chapter 17: Strker
- Exhibit 17-1: Stryker’s BGS Sales, by Country, 2004 (Tabular Format)
- Exhibit 17-2: Stryker’s Bone Graft Substitute Sales, by Country, 2004 (Graphical Format)
- Exhibit 17-3: Stryker’s BMP Sales, by Country, 2004 (Tabular Format)
- Exhibit 17-4: Stryker’s BMP Sales, by Country , 2004 (Tabular Format)
- Chapter 18: Synthes
- Exhibit 18-1: Synthes’ DBM Sales, US, 2004
- Exhibit 18-2: Synthes’ BGS Sales, by Country, 2004 (Tabular Format)
- Exhibit 18-3: Synthes’ BGS Sales, by Country, 2004 (Graphical Format)
- Exhibit 18-4: Synthes Spine’s Machined Bone Sales, US, 2004
- Chapter 19: Tutogen
- Exhibit 19-1: Tutogen BGS Sales, Europe, 2004 (Tabular Format)
- Exhibit 19-2: Tutogen’s BGS Sales, Europe, 2004 (Graphical Format)
- Chapter 20: Wright Medical
- Exhibit 20-1: Wright Medical’s Bone Graft Substitute Sales, by Country, 2004 (Tabular Format)
- Exhibit 20-2: Wright Medical’s Bone Graft Substitute Sales, by Country, 2004 (Graphical Format)
- Exhibit 20-3: Wright Medical’s DBM Sales, US, 2004
- Exhibit 20-4: Wright Medical’s Synthetic BGS Sales, US, 2004
- Chapter 21: Zimmer
- Exhibit 21-1: Zimmer’s Bone Graft Substitute Sales, by Country, 2004 (Tabular Format)
- Exhibit 21-2: Zimmer’s Synthetic Bone Graft Substitute Sales, US, 2004
- Exhibit 21-3: Zimmer’s Bone Graft Substitute Sales, by Country, 2004 (Graphical Format)
AbstractFocus on competitor strategies and new product innovations.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
